BioCryst Pharmaceuticals Stock Forecast, Price & News

9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for BioCryst Pharmaceuticals in the last twelve months. There are currently 5 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" BioCryst Pharmaceuticals stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BCRX, but not buy additional shares or sell existing shares.
View analyst ratings for BioCryst Pharmaceuticals or view top-rated stocks.

9 Wall Street analysts have issued 1 year target prices for BioCryst Pharmaceuticals' stock. Their BCRX stock forecasts range from $13.00 to $30.00. On average, they anticipate BioCryst Pharmaceuticals' stock price to reach $18.10 in the next year. This suggests a possible upside of 68.2% from the stock's current price.
View analysts' price targets for BioCryst Pharmaceuticals or view top-rated stocks among Wall Street analysts.

BioCryst Pharmaceuticals' stock was trading at $13.85 on January 1st, 2022. Since then, BCRX shares have decreased by 22.3% and is now trading at $10.76.
View the best growth stocks for 2022 here.

BioCryst Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for BioCryst Pharmaceuticals.

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) issued its quarterly earnings results on Thursday, May, 5th. The biotechnology company reported ($0.40) earnings per share for the quarter, missing the consensus estimate of ($0.39) by $0.01. The biotechnology company earned $49.92 million during the quarter, compared to analysts' expectations of $50.59 million.
View BioCryst Pharmaceuticals' earnings history.

2 employees have rated BioCryst Pharmaceuticals CEO Jon P. Stonehouse on Glassdoor.com. Jon P. Stonehouse has an approval rating of 40% among BioCryst Pharmaceuticals' employees. This puts Jon P. Stonehouse in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to BioCryst Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Seagen (SGEN), Biogen (BIIB), Alnylam Pharmaceuticals (ALNY), Incyte (INCY), BioMarin Pharmaceutical (BMRN), United Therapeutics (UTHR), Neurocrine Biosciences (NBIX), Repligen (RGEN), Exact Sciences (EXAS), Exelixis (EXEL) and Halozyme Therapeutics (HALO).
View all of BCRX's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other BioCryst Pharmaceuticals investors own include Inovio Pharmaceuticals (INO), El Pollo Loco (LOCO), Advanced Micro Devices (AMD), Idera Pharmaceuticals (IDRA), OPKO Health (OPK), Dynavax Technologies (DVAX), La Jolla Pharmaceutical (LJPC), Novavax (NVAX), Sorrento Therapeutics (SRNE) and VBI Vaccines (VBIV).

BioCryst Pharmaceuticals trades on the NASDAQ under the ticker symbol "BCRX."

BioCryst Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (7.60%), Vanguard Group Inc. (7.12%), State Street Corp (4.02%), Fisher Asset Management LLC (2.15%), Victory Capital Management Inc. (1.91%) and Loomis Sayles & Co. L P (1.27%). Company insiders that own BioCryst Pharmaceuticals stock include Alane P Barnes, Anthony Doyle, George B Abercrombie, George B Abercrombie, Helen M Thackray, Jon P Stonehouse, Kenneth B Lee Jr, Megan Sniecinski, Nancy J Hutson, Vincent Milano, William P Sheridan and Yarlagadda S Babu.
View institutional ownership trends for BioCryst Pharmaceuticals.

BCRX stock was sold by a variety of institutional investors in the last quarter, including Sarissa Capital Management LP, State Street Corp, BlackRock Inc., Deerfield Management Company L.P. Series C, Granahan Investment Management LLC, UBS Group AG, Citigroup Inc., and Group One Trading L.P.. Company insiders that have sold BioCryst Pharmaceuticals company stock in the last two years include Alane P Barnes, George B Abercrombie, Helen M Thackray, Jon P Stonehouse, Nancy J Hutson, William P Sheridan, and Yarlagadda S Babu.
View insider buying and selling activity for BioCryst Pharmaceuticals or view top insider-selling stocks.

BCRX stock was purchased by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Victory Capital Management Inc., Lord Abbett & CO. LLC, Loomis Sayles & Co. L P, Lisanti Capital Growth LLC, Goldman Sachs Group Inc., Ghost Tree Capital LLC, and Renaissance Technologies LLC. Company insiders that have bought BioCryst Pharmaceuticals stock in the last two years include Anthony Doyle, and Vincent Milano.
View insider buying and selling activity for BioCryst Pharmaceuticals or or view top insider-buying stocks.

Shares of BCRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of BCRX stock can currently be purchased for approximately $10.76.

BioCryst Pharmaceuticals (NASDAQ:BCRX) has a market capitalization of $2.00 billion and generates $157.17 million in revenue each year. The biotechnology company earns $-184.06 million in net income (profit) each year or ($1.070010) on an earnings per share basis.

BioCryst Pharmaceuticals employs 358 workers across the globe.

BioCryst Pharmaceuticals was founded in 1986.

BioCryst Pharmaceuticals' mailing address is 4505 EMPEROR BOULEVARD SUITE 200, DURHAM NC, 27703. The official website for BioCryst Pharmaceuticals is www.biocryst.com. The biotechnology company can be reached via phone at (919) 859-1302, via email at [email protected], or via fax at 919-859-1314.